ALung closes $10 million Series B financing round ALung Systems, Inc., a leading programmer of advanced respiratory items, announced today that it has shut a $10 million Series B financing round. These devices is expected to allow patients in order to avoid intubation and invasive mechanical ventilation in many cases. The results of the trial are being reviewed by regulators within the Company’s software for European marketing clearance known as the CE mark. ‘Completing the clinical trial and regulatory submitting for the CE tag had been significant achievements for our firm last year. Our capability to secure this most recent financing in an interval of just four a few months reflects the confidence of our traders in the potential of the Hemolung RAS to make a true difference in the lives of sufferers experiencing acute respiratory failure.’ Participants in the funding included existing shareholders, co-investors of Eagle Ventures, and Birchmere Ventures.Two patients died after crossing over: one due to central nervous system hemorrhage in the context of long-standing, badly managed hypertension and the various other owing to multiorgan failing and hypovolemic shock with a precipitous and unexplained drop in the hemoglobin level in association with a positive fecal occult-blood test. Discussion RESPONSE showed that ruxolitinib was effective in achieving both composite primary end point and its individual components and in reducing symptoms in patients with polycythemia vera who had an inadequate response to or had unacceptable side effects from hydroxyurea. Although many patients with polycythemia vera have an adequate response to hydroxyurea, a subgroup of patients have unacceptable side effects or an inadequate response,13 and alternative treatment plans are needed for these patients.15,16 Furthermore, some patients have a symptom burden that is as high as that in myelofibrosis,3,17,18 including itching, fatigue, and night sweats, which respond to standard therapies poorly.